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ABSTRACT
Despite ubiquitous activation in human cancer, essential downstream effector
pathways of the MYC transcription factor have been difficult to define and target. Using
a structure/function-based approach, we identified the mitochondrial RNA polymerase
(POLRMT) locus as a critical downstream target of MYC. The multifunctional POLRMT
enzyme controls mitochondrial gene expression, a process required both for
mitochondrial function and mitochondrial biogenesis. We further demonstrate that
inhibition of this newly defined MYC effector pathway causes robust and selective
tumor cell apoptosis, via an acute, checkpoint-like mechanism linked to aberrant
electron transport chain complex assembly and mitochondrial reactive oxygen species
(ROS) production. Fortuitously, MYC-dependent tumor cell death can be induced by
inhibiting the mitochondrial gene expression pathway using a variety of strategies,
including treatment with FDA-approved antibiotics. In vivo studies using a mouse
model of Burkitt’s Lymphoma provide pre-clinical evidence that these antibiotics can
successfully block progression of MYC-dependent tumors.

INTRODUCTION

regulates expression of several thousand genes in order to
drive cell cycle progression and malignant transformation
[2, 3]. Among this array of MYC targets, it remains
unclear which genes play an essential role in malignant

Overexpression of the c-MYC oncogene occurs in
most human cancers [1]. The MYC transcription factor
www.impactjournals.com/oncotarget

72395

Oncotarget

RESULTS

transformation. The identification of this essential subset
of MYC targets is important for two main reasons. First,
they may provide an understanding of which cellular
pathways and processes MYC regulates to reprogram
cellular physiology. Second, these targets may serve
as points of therapeutic intervention in the face of our
historic inability to target MYC directly. To address this
knowledge gap, we previously performed a structurefunction based screen to identify MYC targets linked
to malignant transformation [4]. This screen identified
a subset of ~20 MYC targets as specifically correlated
with transformation [4]. Of this small number of genes,
subsequent empirical analysis has confirmed that several
play critical roles in the MYC pathway [5, 6]. Among
the genes identified by this screen was that encoding the
mitochondrial RNA polymerase (POLRMT), also known
as mtRNAP.
POLRMT encodes the rate-limiting RNA
polymerase enzyme which controls transcription of the
small, circular mitochondrial genome [7]. POLRMT
also contributes to mitochondrial gene expression by
regulating mtDNA replication via generation of RNA
primers [8], and interacting with the mitochondrial rRNA
methyltransferase TFB1M to mediate proper assembly of
the small mitochondrial ribosome subunit [9].
The mitochondrial proteome is encoded by distinct
nuclear and mitochondrial genomes. It is well-established
that MYC drives the nuclear-encoded portion of the
mitochondrial biogenesis program [10, 11]. The discovery
of POLRMT as an essential target of MYC provides a
mechanistic explanation for how MYC also regulates
mitochondrial genome transcription in order to fully
reprogram mitochondrial function.
Transport of electrons is one of the essential
processes within mitochondria and occurs via the five
complexes of the electron transport chain (ETC). Four
of these complexes consist of subunits encoded by both
nuclear- and mitochondrial-encoded genes. Remarkably,
interference with MYC’s ability to induce mitochondrial
transcription results in an imbalance in electron transport
chain complex components, induction of mitochondrial
ROS and ultimately converts the cellular response to
MYC activation from cell proliferation to apoptosis.
These effects are specific to tumor cells harboring MYC
activation and can be exploited in vivo using tetracycline
family antibiotics to block mitochondrial translation.
Inhibition of this pathway fully eradicated tumor
formation in the Eµ-myc transgenic model of human
Burkitt’s Lymphoma.

www.impactjournals.com/oncotarget

MYC controls transcription of the gene encoding
the mitochondrial RNA polymerase POLRMT
The oncogenic transcription factor MYC binds to
several thousand loci in the human genome [12]. However,
it remains unclear which of these MYC targets are
essential for MYC function (reviewed in [13]). To refine
our understanding of MYC targets specifically relevant
to malignant transformation, we conducted an expression
profiling screen designed to identify downstream targets
whose transcriptional activation correlates with cellular
transformation [4]. We report here that the nuclearencoded mitochondrial RNA polymerase gene POLRMT
is a direct MYC target. In brief, primary human fibroblast
cells were engineered to express oncogenic levels of MYC
via a conditional allele in which MYC is fused to a mutated
portion of the estrogen receptor (ER). This fusion protein
allows for induction of oncogenic MYC activity upon
treatment with the estrogen analog 4-hydroxytamoxifen
(4-OHT) [14]. As validation, the kinetics and absolute
level of POLRMT induction upon 4-OHT treatment were
found to be similar to those of the well-characterized MYC
target gene CAD, whereas the non-target gene PCAF was
unaffected by MYC activation. (Figure 1A). Supporting
this, the study which first demonstrated the role of MYC
in mitochondrial function identified POLRMT as one of
281 mitochondrial ontology genes among a total of 2679
MYC responsive genes [11].
Levels of ectopic MYC used in Figure 1A mimic
those in human tumors where MYC is amplified or
translocated. To more rigorously assess the physiological
relevance of POLRMT induction, we examined whether
endogenous MYC also regulates POLRMT transcription.
For this purpose, endogenous MYC was depleted from
a panel of cell lines from different lineages using both
genetic and biochemical methods. In order to assess
POLRMT expression in a variety of cell lines exhibiting
endogenous MYC overexpression, the human Burkitt’s
lymphoma cell line Raji was used in addition to the
epithelial line H1299 to represent a lymphoid model with
MYC translocation. In the non-small cell lung cancer cell
line H1299, depletion of MYC via shRNA led to a decrease
in POLRMT protein (Figure 1B). As an alternative method
of depleting endogenous MYC levels, cells were treated
with the BET bromodomain inhibitor JQ1, which inhibits
MYC protein and transcript levels [15]. In Raji cells,
treatment with JQ1 led to a decrease in POLRMT mRNA
and protein, concomitant with decreased MYC (Figure
1C). Additionally, JQ1 treatment of the primary human
fibroblast line LG1 and the acute myeloid leukemia cell
line NOMO-1, the cell lines used to originally characterize
the effect of JQ1 on MYC expression, led to decreased
72396
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Figure 1: POLRMT is a direct transcriptional target of the MYC oncoprotein. A. 2091 MYC/ER cells were treated with

4-hydroxytamoxifen (4-OHT) to induce MYC activity. Cells were harvested at the indicated time points and analyzed by quantitative realtime PCR (qRT-PCR) to show the kinetics of gene induction. Error bars represent SD, n = 3. B. H1299 cells were infected with lentiviral
MYC shRNA or Luciferase (Luc) shRNA as a control. Cells were harvested and whole cells lysates were analyzed by Western blot for the
indicated proteins. C. Raji cells were treated with JQ1 to deplete MYC levels. Cells were harvested and whole cell lysates were analyzed
by Western blot (left) for the indicated proteins and qRT-PCR (right) for POLRMT expression. Error bars represent SD, n = 3. D. Mammary
tumors were induced in six week old female bitransgenic MMTV-rtTA;TetO-MYC mice via administration of 2 mg/mL doxycycline in
drinking water. After mammary tumor formation, doxycycline was withdrawn from the water of 4 mice (MYC OFF) while the other mice
were maintained on doxycycline (MYC ON). 96 hours after doxycycline withdrawal, tumors were harvested and mRNA analyzed by
qRT-PCR. Error bars represent SD, n = 4. ***p < .001 Student’s t-test (two-sided). E. Modified image taken from UCSC genome browser
(Assembly GRCh37/hg19) ENCODE transcription factor ChIP track showing MYC binding at the POLRMT locus in a variety of cell lines
(http://genome.ucsc.edu).
www.impactjournals.com/oncotarget
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levels of POLRMT mRNA (Supplemental Figure S1A).
Considered together, these data suggest that MYC is an
essential regulator of the mitochondrial RNA polymerase
POLRMT in a broad array of tumor cell lineages.
To assess whether the findings linking MYC
and POLRMT expression extend to an in vivo setting,
POLRMT mRNA expression was quantified in tumors
from a mouse model of MYC-driven mammary cancer. In
these animals, MYC expression is mammary gland specific
and doxycycline-inducible [16]. Tumors were induced
in 6-week old mice and after appearance of palpable
mammary tumors, a subset of mice were withdrawn from
doxycycline to inhibit MYC expression. Analysis of
mRNA levels from harvested tumors demonstrated that
POLRMT transcript levels tightly correlate with MYC
activity in vivo, with a significant decrease in POLRMT
mRNA observed in mice when MYC activity was reduced
even briefly (Figure 1D). Furthermore, analysis of TCGA

datasets using the cBioPortal for Cancer Genomics
indicated a correlation between MYC amplification and/
or increased mRNA expression and increased POLRMT
mRNA expression in cancer patient samples. For example,
datasets for glioblastoma and breast invasive carcinoma
reveal a significant correlation between MYC and
POLRMT, with p values of < 0.001 and .002, respectively
[17, 18]. In addition, when analyzed using the Oncomine
Cancer Profiling Database (www.oncomine.org), both
MYC and POLRMT, as well as established MYC
targets LDHA and BAG1, are overexpressed in Burkitt’s
lymphoma samples compared to normal B lymphocytes
(Supplemental Figure S1B) [19]. Similarly, several cancer
types including colorectal cancers, diffuse large B cell
lymphoma, and multiple myeloma display increased
POLRMT expression correlated with increased MYC
expression in cancer cells compared to normal control
cells (Supplemental Figure S1C) [20-22].

Figure 2: MYC regulates mitochondrial transcription and mtDNA replication via POLRMT. A. H1299 cells were

transfected with MYC siRNA or GFP siRNA as a control. 24 hours post-transfection, one group of MYC depleted cells was infected with
lentivirus expressing human POLRMT (P) or the empty vector (vec). Three days post-transfection, cells were harvested and mitochondrial
proteins POLRMT, TFAM, HSP60 and Porin were measured from purified mitochondria. The level of MYC depletion was evaluated from
whole cell lysates. B. Cells described in (A) were analyzed by qRT-PCR for mitochondrial gene expression. Nuclear gene SMYD2 was used
as a control. Error bars represent SD, n = 3. C. Map of the human mitochondrial genome indicating ORF, tRNA, rRNA and gene locations.
Locations of the primer sets used for quantifying mtDNA genome in (D) are indicated (red bars labeled 1-5). D. Total cellular DNA from
cells described in (A) was quantified by qPCR using primer sets shown in (C). Primers amplifying a region at 3p24 were used to validate
the specificity of the mitochondrial/nuclear comparison. Error bars represent SD, n = 3.
www.impactjournals.com/oncotarget
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were identified. In silico analysis of the ENCODE
transcription factor track in the UCSC genome browser
showed MYC binding at multiple E-box sequences within
the POLRMT locus in a variety of human cell types
(Figure 1E) [23, 24]. The direct binding of MYC to the

To address whether POLRMT represents a primary
target of MYC, the binding of endogenous MYC to the
POLRMT locus was evaluated. Within the genomic
sequence of POLRMT, several matches to the consensus
high-affinity binding site (E-box) for MYC/MAX dimers

Figure 3: Synthetic Lethal Dependency of Deregulated MYC on POLRMT. A. U2OS MYC/ER cells were infected with

lentiviral POLRMT shRNA or Luciferase (Luc) shRNA as a control. Five days post-infection cells were seeded at equal densities and MYC
activity was induced via treatment with 4-OHT (MYC On). Cells were counted on day three and day five post MYC-activation. shPOLRMT
cell counts are shown with an adjusted scale (right). Error bars represent SD, n = 3. ***p < .001, Unpaired t-test. B. U2OS MYC/ER cells
were depleted of POLRMT and treated with 4-OHT (MYC On), as in (A). Cells were harvested on day three post MYC-activation and
stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of the percent Annexin V positive
cells (right) are shown. Error bars represent SEM, n = 18. ***p < .001; n.s., not significant, Unpaired t-test. C. U2OS MYC/ER cells were
infected with two distinct lentiviral POLRMT shRNA plasmids (P1 and P2) or shLuc. Five days post-infection MYC was activated via
treatment with 4-OHT (MYC On). Cells were harvested three days post MYC activation and whole cell lysates were analyzed by Western
blot for the indicated proteins. D. HCT116 cells were infected with lentiviral POLRMT shRNA and/or MYC shRNA, or Luciferase shRNA.
Five days post-infection cells were harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and
quantification of percent of Annexin V positive cells (right) is shown. Error bars represent SEM, n = 3. **p < .01; n.s., not significant,
Unpaired t-test. E. Whole cell lysates of cells described in (D) were analyzed by Western blot for the indicated proteins. Casp-3, caspase-3;
FL, full length; CL, cleaved.
www.impactjournals.com/oncotarget
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POLRMT locus is also supported by genome-wide studies
in murine embryonic stem cells showing occupancy of this
region 5’ of the POLRMT locus by MYC, using ChIPseq [25]. We empirically confirmed specific recruitment
of endogenous MYC to these sites by ChIP in the primary
human fibroblast cell line 2091 (Supplemental Figure
S1D).

in a partial loss of the mitochondrial transcription factor
TFAM, an established MYC target [11]. Decreases in
POLRMT and TFAM were not a result of a general
defect in the importation of nuclear-encoded proteins
into the mitochondria, since HSP60 protein levels in
the mitochondria were not affected by MYC depletion.
In order to assess whether the MYC-dependent loss of
POLRMT results in a defect in mitochondrial transcription,
qRT-PCR was performed for the mitochondrial-encoded
genes ND2, ND4, CytB, ATP6 and 12S, as well as the
nuclear gene SMYD2 (Figure 2B). This analysis revealed
that depletion of MYC caused a decrease in all five of
the mitochondrial transcripts assessed. SMYD2, which
is not a MYC target, was unaffected by MYC depletion.
In MYC-depleted cells, restoring POLRMT levels by
ectopic expression (Figure 2A) was sufficient to rescue
the mitochondrial transcripts to normal levels (Figure 2B),
confirming that POLRMT is the limiting factor in their
expression.
MYC regulates mitochondrial biogenesis [11],
a process that requires increased mitochondrial DNA

MYC controls mitochondrial transcription and
mitochondrial genome content via POLRMT
induction
As discussed, POLRMT catalyzes transcription
of the 16.6kb mitochondrial genome. To determine
whether MYC controls mitochondrial gene expression
via POLRMT induction, expression of a panel of
mitochondrial genes was assessed in H1299 cells. Western
blot analysis of mitochondrial lysates from these cells
confirmed that MYC depletion resulted in the loss of
POLRMT (Figure 2A). MYC knockdown also resulted

Figure 4: Synthetic lethality can be induced via treatment with 2’C Methyladenosine (2’CMeA). A. U2OS MYC/ER cells

were treated with increasing concentrations of 2’CMeA, as indicated. MYC activity was induced via treatment with 4-OHT (MYC On).
Three days post MYC-activation cells were harvested and stained with Annexin V and 7-AAD (left). Quantification of percent Annexin
V positive cells at 30µM 2’CMeA dose is shown (middle). Expression of mitochondrial transcript ND4 was assessed by qRT-PCR (right).
Error bars represent SEM (middle) and SD (right), n = 7. *p< .01; n.s. not significant, Unpaired t-test. B. HCT116 cells were infected with
lentiviral MYC shRNA or Luciferase (Luc) shRNA and treated with 30µM 2’CMeA. Cells were harvested and stained with Annexin V and
7-AAD. A representative flow cytometry analysis (left) and quantification of percent Annexin V positive cells (middle) are shown. Whole
cell lysates were analyzed by Western blot for the indicated proteins (right). Error bars represent SEM, n = 3. *p < .01; n.s., not significant,
Unpaired t-test. Casp-3, caspase-3; FL, full length; CL, cleaved; UT, untreated.
www.impactjournals.com/oncotarget
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(mtDNA) synthesis. In addition to its role in gene
expression, POLRMT also primes mtDNA replication [26,
27], contributing to formation of the D loop structure at the
major origin of DNA replication within the mitochondrial
genome [28]. This raises the possibility that POLRMT
induction might explain the role of MYC in mitochondrial
genome replication. In support of this model, MYCdepleted H1299 cells displayed a significant decrease
in mitochondrial genome content when assessed at five
independent regions of the mitochondrial genome (Figure
2C and 2D). Upon expression of ectopic POLRMT,
mitochondrial genome content was fully rescued. In
contrast, nuclear DNA content was unaffected by MYC
depletion or POLRMT expression, as quantified at the
control locus 3p24.

While the conditional MYC/ER allele has been used
extensively to mimic oncogenic levels of MYC function
[14, 30], it was also important to assess the relevance
of POLRMT under more physiological conditions. For
this purpose, HCT116 colon carcinoma cells, which
express high levels of endogenous MYC (Supplemental
Figure S2B), were depleted of POLRMT, MYC, or both
POLRMT and MYC using shRNA. Levels of apoptosis
were then analyzed (Figures 3D and 3E). Annexin V
staining revealed that cells with low POLRMT expression
and high endogenous MYC displayed increased apoptosis
(Figure 3D). Furthermore, depletion of MYC in addition
to depletion of POLRMT rescued cell viability to a normal
level. Apoptosis was also observed upon POLRMT
depletion, as assessed using caspase-3 cleavage and PARP
cleavage as markers (Figure 3E). As with Annexin V
staining, apoptosis measured by caspase-3 cleavage and
PARP cleavage were reduced upon depletion of MYC. To
further extend these findings in another cell line expressing
high endogenous MYC, Raji Burkitt’s lymphoma cells
were depleted of POLRMT using shRNA. In these cells,
MYC is expressed at very high levels due to chromosomal
translocation [31]. Consistent with the observations made
in HCT116 cells, a decrease in POLRMT expression
in combination with oncogenic, endogenous MYC
expression led to increased apoptosis in Raji cells, as
evaluated by Annexin V staining (Supplemental Figures
S2C and S2D). These data confirm that POLRMT
depletion is synthetically lethal with oncogenic levels of
MYC, in a variety of human cancer cell lineages.

POLRMT inhibition is synthetically lethal with
oncogenic levels of MYC
As described earlier, POLRMT was identified
in a screen for MYC targets correlated with malignant
transformation [4]. To assess the functional requirement
for POLRMT as a downstream MYC effector, the extent
to which MYC-overexpressing cells require POLRMT
was tested. A human osteosarcoma line U2OS expressing
a conditional MYC/ER allele was used for this analysis,
as these cells display robust MYC-dependent changes
in either cell proliferation or apoptosis, depending on
cellular contexts [29]. POLRMT was depleted from these
cells using shRNA and cells were plated at equal numbers
prior to MYC activation via treatment with 4-OHT.
Over the course of 5 days, cell numbers were quantified
(Figure 3A). The cells used in this experiment proliferate
rapidly independent of MYC/ER activity. As expected,
activation of MYC resulted in a small increase in cell
number. In contrast, in cells where POLRMT induction
was blocked, activation of MYC resulted in a substantial
decrease in cell number. Apoptosis assays (both Annexin
V staining and Western blotting for caspase-3 cleavage)
demonstrated that this decrease in cell number resulted
from a significant increase in apoptosis under conditions
of MYC activation and POLRMT depletion (Figures
3B, 3C and S2A). Depletion of POLRMT without MYC
activation slowed proliferation, but did not significantly
affect cell viability (Figure 3A and 3B). Thus, loss of
POLRMT induction was synthetically lethal only with
oncogenic levels of MYC activation. These observations
were consistent over the course of multiple experiments,
using multiple shRNA molecules to target POLRMT
(Figures 3B and 3C). Though levels of apoptosis are less
than 100%, a clonogenic assay was performed to assess
the replicative potential of surviving cells. Consistent with
the proliferation assay discussed above, the remaining
cells under synthetic lethal conditions did not exhibit
significant replicative potential (data not shown).
www.impactjournals.com/oncotarget

Synthetic
lethality
can
be
induced
pharmacologically via treatment with 2’CMeA
In humans, very little structural similarity exists
between POLRMT and the nuclear RNA polymerase
molecules. Instead, human POLRMT is related to the
T7 family of prokaryotic enzymes [32-34]. Thus, drugs
that target POLRMT might have little effect on the other
human RNA polymerase enzymes. Structural analysis
and in vitro enzymatic assays show that polymerization
of RNA by POLRMT is inhibited by 2’-C-methyladenosine (2’CMeA) [35]. Empirical analysis confirmed
that treatment of U2OS cells with 2’CMeA, which
is converted efficiently to 2’-C-methyl-ATP once
taken up by cells, results in a dose-dependent block in
mitochondrial transcription without a measurable effect
on nuclear transcription (Supplemental Figure S3A).
This compound was therefore used to assess whether
blocking the enzymatic activity of POLRMT via a small
molecule strategy results in synthetic lethality with MYC
activation, as was observed when POLRMT levels were
reduced using shRNA. Treatment of U2OS MYC/ER
cells with 2’CMeA had no significant effect on viability
in the absence of MYC activation (Figure 4A). As shown
72401
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previously, MYC activation also had no significant
effect on viability (Figures 3B and 4A). However, when
POLRMT inhibition by 2’CMeA was combined with
MYC activation, synthetic lethality was observed in
a dose-dependent manner (Figure 4A). Inhibition of
POLRMT by 2’CMeA was also synthetically lethal with
oncogenic levels of endogenous MYC (Figures 4B and
S3B). HCT116 cells treated with 2’CMeA exhibited high
levels of apoptosis when MYC was present, while cells
depleted of MYC by shRNA reverted to a basal level
of apoptosis. Coupled with the findings from POLRMT
shRNA studies, these data suggest that MYC activation
programs the cell to become strictly dependent on an
essential function of POLRMT for survival.

Inhibition of mitochondrial translation
synthetically lethal with oncogenic MYC

effect human mitochondrial ribosomes and mitochondrial
protein synthesis [38]. Fortuitously, several FDAapproved antibiotics work via this mechanism. Supporting
this as a potential therapeutic strategy in human cancer,
recent studies have shown that targeting mitochondrial
translation (and transcription) using antibiotics induced
apoptosis of acute myeloid leukemia (AML) cells [39, 40].
However, no link to MYC levels was explored in the AML
cells and the mechanism responsible for the sensitivity of
cancer cell lines to blocking mitochondrial translation
was not determined. In order to gain mechanistic insight
into the apoptosis we have observed, we explored the
effect of antibiotics that block mitochondrial translation
in our MYC-inducible system. Upon MYC activation in
U2OS MYC/ER cells, apoptosis was induced in response
to chloramphenicol in a dose dependent manner (Figure
5D). Similarly, U2OS MYC/ER cells are sensitive to
tigecycline, only in the presence of activated MYC (Figure
5E). Collectively, these results demonstrate that MYCoverexpressing cells are dependent on proper expression
of mitochondrial encoded proteins for cell survival, a
dependency that can be exploited using antibiotics to
selectively induce the death of tumor cells expressing
oncogenic levels of MYC.

is

In order to identify the essential function provided
by POLRMT to MYC overexpressing cells, we explored
the pathway of mitochondrial gene expression at multiple
points of regulation. As discussed above, POLRMT is the
rate-limiting enzyme of mitochondrial transcription and
is also responsible for regulation of mtDNA replication
[7, 26]. More recently, POLRMT was discovered to play
a transcription-independent role via its interaction with a
mitochondrial ribosomal RNA methyltransferase TFB1M
[9]. The interaction between TFB1M and POLRMT is
necessary to regulate mitochondrial ribosome assembly,
and disruption of POLRMT expression leads to changes
in steady-state levels of mitochondrial-encoded proteins.
Thus, POLRMT is a critical regulator of mitochondrial
translation, in addition to its roles in mitochondrial
transcription and mtDNA replication. To functionally
dissect the dependence of MYC-overexpressing cells on
elevated mitochondrial gene expression, we inhibited
mitochondrial translation in cells with oncogenic levels
of MYC. Consistent with results using POLRMT shRNA,
synthetic lethality was phenocopied when the POLRMT
interaction partner TFB1M was depleted from HCT116
cells expressing high MYC levels (Figures 5A-5C), but
there is a lack of significant apoptosis under conditions
where MYC is depleted. Thus, blocking mitochondrial
gene expression at the level of translation triggers the
rapid death of MYC overexpressing cells. Supporting
this, the Amati group recently found depletion of other
components of the mitochondrial translation machinery
to be synthetically lethal with oncogenic MYC, and we
have also confirmed these results (Supplemental Figure
S4) [36].
Several classes of antibiotics target bacterial
ribosomes and prevent protein synthesis [37]. The
bacterial translation machinery shares homology with
the mitochondrial translation machinery in humans and
therefore antibiotics targeting bacterial ribosomes also
www.impactjournals.com/oncotarget

Tigecycline effectively reduces tumor burden in
vivo
Results showing that the FDA-approved drugs
chloramphenicol and tigecycline can be used to
target MYC-driven cancer cells in vitro prompted an
examination of the effect of this treatment in vivo.
Tigecycline is in wide clinical use [41] and has recently
completed a Phase I clinical trial for the treatment of
AML (clinicaltrials.gov ID: NCT01332786), based on
the pre-clinical data mentioned above [39, 40]. To define
the role of MYC in this phenomenon, an in vivo model of
MYC-driven lymphomas was used to test the efficacy of
tigecycline on preventing tumor progression. Mice were
inoculated with GFP-expressing Eµ-myc lymphoma cells
and treated with tigecycline or vehicle control (Figure
6). The transplantable lymphoma line derives from a
primary tumor generated in mice which express the EµMYC transgene which mimics the translocation of MYC
to the IgH locus that is diagnostic of Burkitt’s lymphoma
[31, 42]. Mice inoculated intravenously with lymphoma
cells derived from these primary tumors rapidly develop
lymphomas and typically succumb to the disease within
30 days [43, 44]. However, treatment of these mice with
tigecycline resulted in a dramatic reduction of the tumor
burden, measured by white blood cell count and GFPexpressing cell count, and a subsequent improvement
in overall survival. The experimental design included
two arms of the study to explore therapeutic as well
as preventative treatments. Mice were treated with
72402
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Figure 5: Inhibition of mitochondrial translation phenocopies synthetic lethality resulting from POLRMT inhibition.

A. HCT116 cells were infected with lentiviral MYC shRNA and/or TFB1M shRNA or Luciferase (Luc) shRNA. Five days post-infection
cells were harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of percent
Annexin V positive cells (right) is shown. Error bars represent SEM, n = 5. *p < .05; n.s., not significant, Unpaired t-test B. Whole cell
lysates of cells described in (A) were analyzed by Western blot for indicated proteins. C. Relative mRNA expression of cells described in
(A) was measured by qRT-PCR. Error bars represent SD, n = 5. D. U2OS MYC/ER cells were treated with increasing concentrations of
chloramphenicol, as indicated. MYC activity was induced via treatment with 4-OHT (MYC On). Three days post MYC-activation cells
were harvested and stained with Annexin V and 7-AAD (left). Quantification of percent Annexin V positive cells at 40µg/mL dose is shown
(right). Error bars represent SEM, n = 8. ***p < .0001; n.s., not significant, Unpaired t-test E. U2OS MYC/ER cells were treated with
10µM tigecycline (Tig) and MYC activity was induced via treatment with 4-OHT (MYC On). Three days post MYC-activation cells were
harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of percent Annexin
V positive staining cells (right) is shown. Error bars represent SEM, n = 7. *p < .05; n.s., not significant, Unpaired t-test. UT, untreated.
www.impactjournals.com/oncotarget

72403

Oncotarget

tigecycline either before (Figures 6A-6C) or after
(Figures 6D-6F) the lymphomas established, as measured
by white blood cell count. Remarkably, mice treated
before tumor development displayed 100% survival
rate for 120 days after lymphoma cells were introduced,
at which time the study was terminated (Figure 6A).
Mice treated with tigecycline simultaneous with tumor
cell inoculation retained a constant and normal number
of white blood cells, whereas control mice displayed
a steady increase in white blood cell count, reflecting
lymphoma progression (Figure 6B). Consistent with this,
GFP staining showed that control mice displayed a high
percentage (approximately 60%) of lymphoma cells, while
mice treated with tigecycline displayed less than 1% GFPpositive cells in blood samples at 19 days post-inoculation
(Figures 6C, S5A and S5B). These results demonstrate
that tigecycline treatment is effective at preventing MYCdriven lymphoma tumor engraftment and increasing
survival in vivo. We also explored the therapeutic benefit
of tigecycline treatment after lymphoma establishment.
Notably, mice treated with tigecycline after lymphomas
were established had approximately 70% survival rate
with little increase in white blood cell count or GFPpositive cells (Figures 6D-6F, S5A and S5B). We presume
that the effects of tigecycline on tumor cell survival are
cell autonomous within the lymphoma cells, but there is
a possibility the host stroma or immune system contribute
to the effect of the drug. However, based on results found
by the Amati group, tigecycline blocks the growth of
MYC-derived lymphomas in vivo, even in the absence of
an immune system (D’Andrea et al 2016, accompanying
paper).
The marked success of tigecycline treatment in
vivo highlights the potential for using this drug clinically
to treat patients with MYC-driven tumors. One possible
constraint of this treatment would be that MYC-dependent
apoptosis relies on functional p53 in some cases. It was
therefore worthwhile to determine whether apoptosis
induced by simultaneous activation of MYC and blockade
of mitochondrial gene expression requires an intact p53
pathway. To assess this potential dependency, isogenic
HCT116 cells were utilized which are either wildtype or null for p53 [45]. In these cells, which express
high endogenous MYC levels, depletion of POLRMT
using two distinct shRNAs resulted in robust induction
of apoptosis in the presence of p53, as measured by
caspase-3 cleavage (Supplemental Figure S5C). In cells
lacking p53 expression, depletion of POLRMT also led
to an increase in caspase-3 cleavage compared to control
cells (Supplemental Figure S5C). Though the levels of
apoptosis were slightly diminished compared to p53 wild
type cells, it is clear that POLRMT depletion remains
synthetically lethal with oncogenic MYC regardless of
p53 status. In vivo support for the p53 independence of
these effects was provided by the fact that the Eµ-MYC
lymphoma cells used in Figure 6 lack functional p53 [46],
www.impactjournals.com/oncotarget

yet remain tigecycline sensitive.

Tight coordination of the nuclear- and
mitochondrial-encoded components of the
mitochondrial program driven by MYC is critical
for tumor cell survival
The results thus far support the hypothesis that
induction of mitochondrial gene expression is required
for the survival of MYC-overexpressing cells. In order to
define the biochemical defect that triggers the apoptosis
of cells expressing elevated MYC and depressed
mitochondrial gene expression, several hypotheses
were explored. One of these hypotheses relates to the
role of MYC in regulating pyrimidine biosynthesis
[47]. An essential step in this pathway involves the
mitochondrial localized dihydrooratate dehydrogenase
enzyme (DHODH), whose catalytic activity is dependent
on ubiquinone as an electron acceptor. Dysfunctional
electron transport chain (ETC) activity prevents
ubiquinone production, and thereby impedes DHODH
and pyrimidine biosynthesis. Rho0 cells, which lack
mtDNA and therefore have defects in DHODH activity
and pyrimidine biosynthesis, can survive if provided with
exogenous uridine [48, 49]. To assess whether defective
DHODH/pyrimidine biosynthesis could explain the
synthetic lethality between MYC activation and POLRMT
inhibition, U2OS MYC/ER cells were treated with uridine
(and pyruvate). Pyruvate is necessary to maintain the
cellular redox balance, which is altered in cells lacking
mitochondrial oxidative phosphorylation due to an
accumulation of NADH. Restoration of a normal redox
state is achieved during the reaction converting pyruvate
to lactate, while NADH is oxidized to NAD+ [49].
Cells supplemented with exogenous uridine displayed
comparable levels of apoptosis to non-supplemented cells
under synthetic lethal conditions (Supplemental Figures
S6A and S6B), suggesting that a defect in pyrimidine
biosynthesis is an unlikely trigger for apoptosis. As an
alternative method to rescue this pathway, the yeast
form of DHODH was expressed in these cells. The yeast
DHODH enzyme is cytoplasmic rather than mitochondrial
and does not require ubiquinone as an electron acceptor
[50, 51]. Expression of this plasmid circumvents the
requirement for ETC function in pyrimidine biosynthesis.
As with the uridine/pyruvate supplementation study,
expression of yeast DHODH did not reverse the synthetic
lethality (Supplemental Figure S6D).
Another biological pathway that links MYC
to mitochondria is one-carbon metabolism [52-54].
The serine hydroxymethyltransferase SHMT2 is a
mitochondrial localized protein and a direct MYC target
[52, 55]. In a screen for functional complementation,
SHMT2 could provide partial rescue of the proliferation
defect of MYC null cells [52]. We were prompted
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Figure 6: Tigecycline inhibits B cell lymphoma, in vivo, prolonging survival. A. and D. Kaplan-Meier survival curves of

C57Bl/6 mice injected intravenously with GFP-expressing Eµ-myc lymphoma cells and administered tigecycline (Tig) or PBS (vehicle
control) starting the day of injection (A, p < 0.0001, log-rank test) or once the lymphoma had established on day nine indicated by an arrow
(D, p < 0.0001, log-rank test). B. and E. For the mice in A and D, respectively, white blood cell counts (WBC) and GFP positive cells
(lymphoma) in the blood, as measured by flow cytometry (C and F, respectively), were determined on the days indicated. The number (n) of
mice in each group is indicated. B, *P = 4.43x10-6, **P = 1.57x10-5; C, *P = 1.58x10-5; **P = 1.57x10-8; E, *P = 7.23x10-4, **P = 9.42x10-6;
F, *P = 4.77x10-7; **P = 4.02x10-9; t-tests.
www.impactjournals.com/oncotarget
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to explore the possibility that a defect in one-carbon
metabolism, due to loss of mitochondrial SHMT2
function, could induce apoptosis in the presence of
oncogenic MYC. However, depletion of SHMT2 in the
presence of oncogenic MYC in U2OS MYC/ER cells had
little effect on cell viability (Supplemental Figure S6E).
These data suggest that MYC-overexpressing cells are
not dependent on mitochondrial one-carbon metabolism
regulated by SHMT2 for survival.
The 13 genes encoded by the mitochondrial genome
produce subunits of the ETC. Together with nuclear
encoded subunits, these proteins form Complexes I,
III, IV and V. As MYC is known to drive mitochondrial
biogenesis and function, the nuclear encoded subunits of
the ETC are overexpressed in the presence of oncogenic
MYC [11]. It is possible that the combinatorial effect of
increasing production of nuclear encoded subunits (due
to high MYC), and simultaneous defects in production
of mitochondrial encoded subunits (e.g. when POLRMT
is depleted), causes an imbalance in the stoichiometry of
subunits within individual ETC complexes. Defects in
proper ETC activity cause release of electrons, thereby
increasing cellular levels of reactive oxygen species
(ROS), which are potent inducers of apoptosis [56-58].
In order to test the hypothesis that the synthetic lethality
is triggered by high cellular ROS levels, we treated
cells with ROS scavengers. U2OS MYC/ER cells were
depleted of POLRMT and treated with 4-OHT to induce
MYC activity, resulting in the synthetic lethal phenotype.
Upon treatment with the ROS scavenger N-Acetyl
Cysteine (NAC), synthetic lethality was partially reversed
(Figure 7A). Similarly, induction of synthetic lethality via
treatment with tigecycline was also rescued with NAC
(Figure 7B). These results support the hypothesis that
MYC coordinately regulates nuclear- and mitochondrialencoded proteins to form a functional ETC, and that
disturbing this balances triggers ROS production and
apoptosis. Thus, cells with oncogenic MYC express high
levels of nuclear-encoded ETC subunits in order to meet
the metabolic demand of rapid growth and proliferation,
but interfering with MYC’s ability to coordinately regulate
mitochondrial-encoded ETC subunits creates an imbalance
in stoichiometry, leading to toxic cellular ROS levels and
apoptosis.
To directly assess whether this imbalance exists, we
analyzed the protein levels of ETC complex subunits that
are labile when their resident complex is misassembled.
As shown in Figure 7C, upon chloramphenicol treatment,
cells lose stability of Complexes I, III and IV. Complex II
is entirely nuclear-encoded, and is therefore unaffected by
inhibition of mitochondrial translation. These observations
are consistent with the synthetic lethality resulting from
an imbalance in the stoichiometry of ETC complexes.
Complex II is therefore overproduced, relative to the other
complexes, presumably leading to release of electrons
and increased levels of apoptosis [58]. To more distinctly
www.impactjournals.com/oncotarget

define the source of ROS production, we performed
synthetic lethality experiments using a ROS scavenger
specific to mitochondrial-produced ROS. This reagent,
MnTBAP, is a superoxide dismutase mimetic that targets
the superoxide molecules produced by free radicals
created during ETC reactions [59, 60]. As shown by
caspase-3 cleavage, synthetic lethality was reversed upon
treatment with MnTBAP (Figure 7D), confirming that
the source of apoptosis is mitochondrial-produced ROS.
Additionally, we directly measured levels of mitochondrial
produced superoxide using the MitoSOX Red assay. As
shown in Figure S6F, there is an increase in mitochondrial
superoxide in cells under synthetic lethal conditions.
Collectively, the data presented in this study indicate
that MYC-overexpressing cells are reliant on elevated
mitochondrial gene expression for proper ETC function
and protection against mitochondrial-produced ROS. We
have shown that this pathway can be targeted as a means
to therapeutically treat MYC-driven cancers, both in vitro
and in vivo. The therapeutic implications of this study are
heightened by the existence of FDA-approved drugs that
target this essential pathway.

DISCUSSION
MYC overexpression is common to the majority
of human cancers, yet attempts to directly target this
oncogene as a therapeutic strategy have historically
proven challenging. This led to the concept that targeting
essential downstream nodes in the MYC pathway might
be a more practical goal [61]. However, MYC regulates
several thousand genes and only a few MYC targets
are documented as required for the survival of MYCoverexpressing cells (i.e. essential downstream nodes)
[13]. Thus, the identification of the essential downstream
targets, from among the thousands of genes regulated
by MYC, has also presented a challenge. Selective
identification of these essential downstream targets
was the rationale for the screen in which POLRMT
was identified (4). The identification of POLRMT as an
essential downstream effector of MYC subsequently led to
the observation that MYC overexpression plays a central
role in controlling the entire gene expression program at
the mitochondrial genome. Furthermore, MYC-mediated
increases in mitochondrial gene expression are critical
to its ability to drive malignancy and blocking MYC’s
upregulation of mitochondrial gene expression triggers an
acute apoptotic response. Notably, this apoptotic response
can be triggered by inhibiting MYC’s upregulation of
mitochondrial gene expression at any of multiple steps,
using either pharmacologic or genetic approaches. As
discussed above, the Amati group recently identified the
mitochondrial translation factor PTCD3 in an RNAi screen
specifically designed to identify genes whose inhibition
results in synthetic lethality with MYC overexpression
(D’Andrea et al 2016, accompanying paper). Considering
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the distinct methodologies and cellular platforms utilized
across the two studies, the convergent discovery of an
essential requirement for enhanced mitochondrial gene
expression adds support to the view that this newly
identified link is of broad importance for MYC function.

The discovery that MYC controls the full
mitochondrial transcription program via its direct
regulation of the nuclear gene encoding the mitochondrial
RNA polymerase also completes the scenario which began
to emerge when MYC was documented to play a direct

Figure 7: Mitochondrial gene expression protects MYC-overexpressing cells from toxic levels of ROS. A. U2OS MYC/

ER cells were infected with lentiviral POLRMT shRNA or Luciferase (Luc) shRNA and treated with NAC. MYC activity was induced via
4-OHT treatment (MYC On). Three days post-treatment cells were harvested and whole cell lysates were analyzed by Western blot for the
indicated proteins (left). Relative mRNA expression was measured by qRT-PCR (right). Error bars represent SD, n = 3. B. U2OS MYC/
ER cells were treated with tigecycline (Tig) and/or NAC. MYC activity was induced via 4-OHT treatment. Three days post-treatment cells
were harvested and whole cell lysates were analyzed by Western blot for the indicated proteins. C. U2OS MYC/ER cells were treated with
chloramphenicol (CAM). MYC activity was induced via 4-OHT treatment. Whole cell lysates were analyzed by Western blot using an
antibody cocktail for subunits of electron transport chain (ETC) complexes, as indicated (I-IV). D. U2OS MYC/ER cells were infected with
lentiviral POLRMT shRNA or Luciferase (Luc) shRNA and treated with MnTBAP. MYC activity was induced via 4-OHT treatment. Three
days post-treatment cells were harvested. Whole cell lysates were analyzed by Western blot for the indicated proteins. Casp-3, caspase-3;
FL, full length; CL, cleaved; UT, untreated.
www.impactjournals.com/oncotarget
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role in regulating all three RNA polymerase molecules that
transcribe the nuclear genome (reviewed in [62]).
As mentioned, our own screen was designed to
exploit the current understanding of the structure/function
relationship of MYC protein domains. For many decades
the highly conserved but functionally enigmatic MbII
domain was known to be essential for MYC’s ability to
drive malignancy [63, 64]. We demonstrated that this
requirement for MbII relates in part to its role in mediating
interactions between MYC and transcriptional coactivator
complexes containing the TRRAP acetyltransferase
partner [65, 66]. Supporting our premise that MYC target
genes linked to essential MYC functions might require
the transcriptional cofactors recruited by the similarly
essential MbII domain, TRRAP itself was identified
by the Grandori group in a recent RNAi screen for
genes whose depletion results in synthetic lethality with
MYC activation [67]. Also consistent with this central
concept, the two previously characterized MYC targets
identified in our MbII-based screen, MTA1 and BAG1,
were subsequently shown to play essential roles in MYC
function [5, 6].
Mechanistically, a number of distinct biochemical
defects could provide the explanation for the synthetic
lethality observed between MYC activation and inhibition
of mitochondrial gene expression. For example, Rho0
cells have a defect in pyrimidine biosynthesis due to
impairment of the mitochondrial-localized DHODH
enzyme and can survive only if supplied with exogenous
sources of pyrimidine [68]. However, exogenous
pyrimidine did not rescue the synthetic lethality observed
here (Supplemental Figures S6A-D), suggesting that
defective pyrimidine biosynthesis/DHODH activity is not
the primary cause of cell death. Similarly, experimental
results have largely eliminated the possibility that MYC’s
role in one carbon metabolism is the point of vulnerability
that explains the synthetic lethality (Supplemental Figure
S6E). Instead, data support a model in which MYC
plays a critical role in enhancing mitochondrial function
and biogenesis, partly via its known role in driving the
nuclear gene expression program that encodes proteins
imported into the mitochondria (10), and partly via the
synchronous upregulation of the mitochondrial gene
expression program, as reported here. In this model,
blockade of the mitochondrial arm of this coordinated
upregulation, whether by shPOLRMT, shTFB1M,
2’CMeA, chloramphenicol or tigecycline treatment, results
in lethality caused by an imbalance in the mitochondrialand nuclear-encoded components of the mitochondria (as
evident in Figure 7C). Aberrant subunit stoichiometry
results in misassembly of ETC complexes, a phenomenon
known to cause electron leakage and subsequent
mitochondrial ROS generation [58]. Consistent with this
model, treatment with the mitochondria specific ROS
scavenger MnTBAP blocks the synthetic lethal phenotype
(Figure 7D). It is also noteworthy that the death observed
www.impactjournals.com/oncotarget

upon POLRMT inhibition in MYC-driven cells is rapid,
resembling more closely a checkpoint-like phenomenon
than the cell death associated with the gradual attrition of
mitochondria as cells proliferate.
Ultimately, these findings have several practical
and conceptual implications for treatment strategies in
oncology. The identification of enhanced mitochondrial
gene expression as a targetable pathway could be rapidly
translated into therapeutic approaches by utilizing FDAapproved compounds that work by mechanisms similar
to tigecycline. As mentioned above, tigecycline itself has
recently completed a Phase I clinical trial for treatment
of AML (clinicaltrials.gov ID: NCT01332786). Based on
TCGA data, MYC is elevated in only 9% of AML patients
and neither the pre-clinical studies nor the AML clinical
trial used MYC as a biomarker of tigecycline sensitivity
[39]. The lack of homology between POLRMT and
other mammalian RNA polymerase molecules also raises
the possibility that targeting POLRMT with inhibitors
mechanistically related to 2’CMeA could also prove
efficacious and selective. The fact that all tested strategies
for inhibiting mitochondrial gene expression have effects
only when MYC is simultaneously expressed at oncogenic
levels, provides optimism that a therapeutic window might
exist between lethal effects of these treatments on tumor
cells and toxicity in non-malignant cells. This principle
appears broadly applicable since the synthetic lethality
was observed in cells of many distinct lineages where
oncogenic MYC levels were achieved by a variety of
means. Also providing optimism for these findings having
broad implications are the data showing that the synthetic
lethality can be observed even in tumor cells lacking
functional p53.
Recent efforts in the design of direct and indirect
MYC inhibitors aim to decrease MYC expression/
function as a therapeutic strategy [69-72]. In contrast, the
findings reported here suggest that exploiting the potent
apoptotic activity provided by MYC overexpression for a
therapeutic advantage might be more advantageous. High
expression (i.e. oncogenic) levels of MYC are required
for apoptosis [73, 74], offering a unique opportunity to
specifically target cancer cells. The approach of exploiting
oncogene overexpression, rather than inhibiting oncogenic
signaling pathways, offers a distinct perspective on the
design of cancer therapies.

MATERIALS AND METHODS
Cell culture
Cell lines were obtained from ATCC. All cells, with
the exception of Raji and IMR90 cells, were maintained
in Dulbecco’s modified Eagle’s medium (DMEM)
(Corning) supplemented with 10% fetal bovine serum
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Target

TRCN

MYC

0000039642

POLRMT-1

0000053114

POLRMT-2

0000053113

PTCD3

0000145035

SHMT2

0000034807

TFB1M

0000021041

Sequence
CCGGCCTGAGACAGATCAGCAACAACTCG
AGTTGTTGCTGATCTGTCTCAGGTTTTTG
CCGGCGGTGGATGTACCCATGCTTTCTCG
AGAAAGCATGGGTACATCCACCGTTTTTG
CCGGGCAGAACCACTACAGGAAGTACTCG
AGTACTTCCTGTAGTGGTTCTGCTTTTTG
CCGGGCTGATATCAAATCTGCGTATCTCG
AGATACGCAGATTTGATATCAGCTTTTTTG
CCGGGCTCCAGGATTTCAAATCCTTCTCG
AGAAGGATTTGAAATCCTGGAGCTTTTTG
CCGGCCACGATTCGAGAAATCATTACTCG
AGTAATGATTTCTCGAATCGTGGTTTTT

Human Gene

Forward Primer

Reverse Primer

12S
ATP6
CAD
CytB
HBO1
MYC
ND2
ND4
PCAF
POLRMT
SHMT2
SMYD2
TFB1M
POLRMT-1 (ChIP)
POLRMT-2 (ChIP)
POLRMT-3 (ChIP)
POLRMT-4 (ChIP)

AAAACTGCTCGCCAGAACACTAC
TCATTCAACCAATAGCCCTGG
TCAAAAGGTGTCCAGTGGGC
CGCATGATGAAACTTCGGCT
TCATGATGAGTCACCGCCTC
GGACGACGAGACCTTCATCAA
GGTTGCTTGCGTGAGGAAAT
CCTAAAGCCCATGTCGAAGC
ACCCTAACCCCTCACCCACT
CGGGTCCCCGAGAACATC
CAAGACTGGCCGGGAGATC
TCATAGCTGTTGCCCCAATG
TGCTTGCCGCGTATCATG
GCTTTCTCTCCTTGCAGCCTC
GGAGTCTACTTCCGGCTGGG
TGCCTTGAGCATTTCCTTCC
CCGCGATGTGTGGTTAGATCT

GCACCCCCAGGTCCTTT
GCCTGCAGTAATGTTAGCGGT
GACAATTCCCAGCCACATGC
ATTTGGAGGATCAGGCAGGC
TCAGAAGAAGGCGCATTTCC
GCCGCTCCACATACAGTCCT
AACCCTCGTTCCACAGAAGCT
TGCGGCAAGTACTATTGACCC
CAATTATTTGCTGCAGGTCGG
GGGAGGCCTCTCACTATCTCGTA
GGGAACACGGCAAAGTTGAT
TCTGCCAGGGTCCCTTTGTA
CGGAGGGAGACGGCAAGT
GCTGGAAGACACAGCACGTG
GTGGTTTCATGGTCGACG
CCAGACAGATTCACGAGCCC
GATTCTGCTGGAACGACCTCC

(FBS) (Gemini). Raji cells were maintained in RPMI
1640 (Corning) supplemented with 10% FBS and 1%
L-glutamine (Corning). IMR90 cells were maintained in
Eagle’s minimum essential medium (EMEM) (Corning)
supplemented with 2mM L-glutamine, 1% nonessential
amino acids (Corning) and 10% FBS.
The MYC/ER fusion protein was activated by
adding 4-hydroxytamoxifen (4-OHT) (Sigma Aldrich) at
a final concentration of 30nM. JQ1 was used as previously
described [75]. The 2’C-methyladenosine (2’CMeA) was
a generous gift of Dr. Joy Feng and Gilead Sciences, Inc
and was added to cell media at concentrations ranging
from 3-30µM. The antibiotics chloramphenicol and
tigecycline were used at concentrations ranging from
13-120µg/mL and10µM, respectively (Sigma Aldrich).
The ROS scavenger N-acetylcysteine (NAC) was
used at a concentration of 5mM (Sigma Aldrich). The
mitochondrial-specific ROS scavenger MnTBAP was used
at a concentration of 100nM (MED Millipore). Exogenous
www.impactjournals.com/oncotarget

uridine and pyruvate were used at concentrations of 50µg/
mL and 100µg/mL, respectively (Sigma Aldrich).

Plasmid expression and lentiviral production
MYC siRNA was obtained from Dharmacon.
GFP siRNA was used as a negative control. Cells were
transfected with 200 nM siRNA per well in 6-well
plates using DharmaFECT 2 (Dharmacon). Cells were
harvested and RNA and protein extracted 72 hours after
transfection. The Plv-based lentiviral expression of human
POLRMT was obtained from Dr. Chumakov. Lentiviral
short hairpin RNA (shRNA) plasmids corresponding to
MYC, POLRMT, TFB1M, SHMT2 and control luciferase
shRNAs were obtained from TRC (Sigma). See below
table for shRNA sequences. All sequences are from listed
5’-3’. Lentiviral packaging plasmids (pCMV-R8.2 and
pCMV-VSV-G) were cotransfected with vectors into 293T
72409
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Proliferation assay

cells. Viral supernatants were collected, filtered, and added
directly to target cells in the presence of 8µg/ml polybrene
(Sigma Aldrich). Cells were selected with puromycin
(Sigma Aldrich) for 24 hours. The yDHODH retroviral
vector was constructed in the packaging vector MIGR1.
Retroviral packaging plasmid Ψ2 was cotransfected with
yDHODH or empty vector into U2OS MYC/ER cells in
the presence of 8µg/mL polybrene. Transfected cells were
isolated by fluorescence-activated cell sorting (FACS) for
the GFP marker expressed from the retroviral vector, 2-3
days post-transfection.

Quantitative
RT-PCR
immunoprecipitation

and

2x105 U2OS MYC/ER cells were plated in complete
medium. After attachment of cells to tissue culture dishes
(approximately 24 hours), cells were treated with 4-OHT
as described above. Cells were harvested and counted by
hemocytometer after 3 and 5 days of treatment.

Apoptosis assays
To quantitate apoptotic cell death, cells were
collected by trypsinization, washed with phosphatebuffered saline and stained using the Annexin V PE7AAD apoptosis detection kit (BD Pharmingen) as
described previously [76]. Fluorescence was detected by
flow cytometry (BD LSRII) and analyzed using FlowJo
software (TreeStar). 10,000 total events were collected and
then subsequently analyzed for the percentage of Annexin
V-PE positive cells.

chromatin

Quantitative RT-PCR (qRT-PCR) was performed
by real-time analysis using the Step One Plus detection
system (Applied Biosystems) and SYBR GREEN PCR
Master Mix kit (Applied Biosystems). RNA was isolated
using the Trizol method (Invitrogen) and cDNA was
then generated using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems).
ChIP was performed as described previously [5],
using chromatin from the primary human fibroblast strain
2091. See below table for primer sequences. All sequences
are listed from 5’-3’.

ROS assay
To quantitate levels of reactive oxygen species, cells
were collected by trypsinization, washed with phosphatebuffered saline, and counted. 200,000 cells were stained
with MitoSOX Red Mitochondrial Superoxide Indicator
(Thermo Fisher). Fluorescence was detected by flow
cytometry (BD LSRII) and analyzed using FlowJo
software (TreeStar). 10,000 total events were collected.

Western blotting
To generate whole cell extracts, cells were lysed
with E1A lysis buffer (20mM NaH2PO4, 150mM NaCl,
0.5% IGEPAL, 5mM EDTA, 50mM NaF, 30mM Sodium
pyrophosphate, 10% Glycerol). The following antibodies
were used to detect protein expression by Western blot,
MYC, actin, p53, H2B (Santa Cruz), POLRMT, Total
OXPHOS Cocktail (Abcam), Caspase-3 (Cell Signaling),
PARP (Biovision), γH2A.X (Millipore), and ORC2 (BD
Bioscience). Western blotting of mitochondrial isolates for
the mitochondrial proteins POLRMT, TFAM, HSP60 and
porin has been described previously [7].

Mice
Female bitransgenic MMTV-rtTA;TetO-MYC
mice [16, 77] were administered 2 mg/mL doxycycline
in drinking water beginning at 6 weeks of age to induce
c-MYC expression in mammary tissue and mice were
palpated weekly to identify mammary tumors. Mammary
tumors were harvested from mice on doxycycline,
as well as from tumor-bearing mice following 96 hr
of doxycycline withdrawal to induce c-MYC downregulation. Tumor tissue was snap frozen and RNA was
extracted and purified as described above.
C57Bl/6 mice (6-11 weeks old) were injected
(intravenous, tail vein) with 2x106 Eµ-myc lymphoma
cells expressing GFP. Tigecycline (100 mg/kg) or PBS
(vehicle control) was injected (intraperitoneal) twice
daily for 3 days followed by once daily for 11 days.
Treatment commenced the day of lymphoma injection
for one cohort of mice (n = 9 per group) or in a second
cohort (n = 12 per group), once the lymphoma had
established (day 9) as determined by elevated (~9-10x103
cells/ml) white blood cell counts. Blood was collected
at intervals to measure white blood cell counts (WBC)
using a FORCYTE Analyzer (Oxford Science) and the

mtDNA quantitation
DNA was collected from whole cell lysates. qPCR
was performed for genomic sequences of the mitochondrial
encoded genes cytochrome c oxidase subunit 1 (COX1),
NADH dehydrogenase subunit 2 (ND2), ATP synthase
6 (ATP6), NADH dehydrogenase subunit 4 (ND4), 12S
rRNA, and the nuclear gene peroxisome proliferative
activated receptor gamma coactivator- related 1 (PPRC1).
Absolute COX1, ND2, ATP6, ND4 and 12S DNA
copies were normalized to nuclear genome content, as
represented by PPRC1 signals. As a control, a nuclear
genome sequence at 3p24 was amplified.
www.impactjournals.com/oncotarget
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percentage of GFP positive lymphoma cells using flow
cytometry (see below). All mice were carefully monitored
and sacrificed at humane endpoints as the lymphoma
progressed. All surviving mice were sacrificed on day
129 or 126 following lymphoma injection for the first
or second cohort, respectively. Kaplan-Meier analyses
were performed and log-rank tests determined statistical
significance for survival (GraphPad Prism).
Whole blood (30 ml) was drawn from each mouse
at intervals. Following hypotonic lysis of red blood
cells, GFP positive cells (lymphoma) were measured by
flow cytometry (BD FACSCanto II) and analyzed using
FlowJo software (TreeStar). Lymph nodes were removed
from surviving mice at the end of the study. Single cell
suspensions were prepared from the lymph nodes and
subjected to flow cytometry.
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